Treatment of Relapsed/Refractory Acute Lymphoblastic Leukemia 

  Abstract: Patients with relapsed or refractory acute lymphoblastic leukemia (R/R ALL) have dismal outcomes, with survival of less than 6 months, and treatment options in […]

Tisagenlecleucel in Pediatric Patients With Acute Lymphoblastic Leukemia

  H&O  What is tisagenlecleucel? SM  Tisagenlecleucel (Kymriah, Novartis) is an engineered T-cell therapy that uses a chimeric antigen receptor (CAR) to redirect the cytotoxic machinery […]